We read with interest the article by Sircar et al1 on febuxostat efficacy for retarding chronic kidney disease (CKD) progression in hyperuricemic patients. The authors reported that estimated glomerular filtration rates (eGFRs) had a >10% decline in 38% of participants in the febuxostat group compared with 54% in the placebo group (P